Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Accured Expenses (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Accured Expenses for 16 consecutive years, with -$301.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 3.43% to -$301.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.4 million, a 192.33% increase, with the full-year FY2025 number at $55.4 million, up 192.33% from a year prior.
  • Change in Accured Expenses was -$301.7 million for Q4 2025 at Dexcom, down from $341.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $449.9 million in Q4 2023 to a low of -$301.7 million in Q4 2025.
  • A 5-year average of $24.0 million and a median of $21.6 million in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 1293.62% in 2023, then surged 586.35% in 2025.
  • Dexcom's Change in Accured Expenses stood at -$118.5 million in 2021, then plummeted by 37.38% to -$162.8 million in 2022, then surged by 376.35% to $449.9 million in 2023, then crashed by 164.84% to -$291.7 million in 2024, then fell by 3.43% to -$301.7 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Change in Accured Expenses are -$301.7 million (Q4 2025), $341.8 million (Q3 2025), and -$110.1 million (Q2 2025).